406 related articles for article (PubMed ID: 26657098)
1. [An updated overview of the high intensity lipid lowering therapy in high cardiovascular risk patients].
Pedro-Botet J; Pintó X
Clin Investig Arterioscler; 2016; 28(1):19-30. PubMed ID: 26657098
[TBL] [Abstract][Full Text] [Related]
2. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
Bruckert E; Ferrières J
Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
[TBL] [Abstract][Full Text] [Related]
3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
4. [Inhibitors of PCSK9].
Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
[TBL] [Abstract][Full Text] [Related]
5. [Statins in primary prevention of coronary heart disease].
Paulweber B
Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
Okere AN; Serra C
Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
[TBL] [Abstract][Full Text] [Related]
7. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
Filardi PP; Paolillo S; Trimarco B
G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
[TBL] [Abstract][Full Text] [Related]
8. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
9. Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
Soran H; Adam S; Durrington PN
Atherosclerosis; 2018 Nov; 278():135-142. PubMed ID: 30273874
[TBL] [Abstract][Full Text] [Related]
10. Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat.
Soran H; Adam S; Durrington PN
Eur J Prev Cardiol; 2017 Jan; 24(1):76-83. PubMed ID: 27609614
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol treatment and changes in guidelines in an academic medical practice.
Schoen MW; Salas J; Scherrer JF; Buckhold FR
Am J Med; 2015 Apr; 128(4):403-9. PubMed ID: 25460526
[TBL] [Abstract][Full Text] [Related]
12. [Guidelines for the management of dyslipidemia].
Díaz Rodríguez Á;
Semergen; 2014 Sep; 40 Suppl 4():19-25. PubMed ID: 25595349
[TBL] [Abstract][Full Text] [Related]
13. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.
Maddox TM; Borden WB; Tang F; Virani SS; Oetgen WJ; Mullen JB; Chan PS; Casale PN; Douglas PS; Masoudi FA; Farmer SA; Rumsfeld JS
J Am Coll Cardiol; 2014 Dec; 64(21):2183-92. PubMed ID: 25447259
[TBL] [Abstract][Full Text] [Related]
14. Hypercholesterolemia As a Risk Factor for Cardiovascular Disease: Current Controversial Therapeutic Management.
Zárate A; Manuel-Apolinar L; Saucedo R; Hernández-Valencia M; Basurto L
Arch Med Res; 2016 Oct; 47(7):491-495. PubMed ID: 28262189
[TBL] [Abstract][Full Text] [Related]
15. [Are treatments with statins that are considered unsuitable really unsuitable?].
Estrada Alifonso C; Vilaseca Canals J; Méndez Trías MÁ; Lozano Ovalle S; Jusmet Miquel J; Torres Machado V; Castro Rivera E
Clin Investig Arterioscler; 2015; 27(4):175-8. PubMed ID: 26249020
[TBL] [Abstract][Full Text] [Related]
16. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
18. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
19. Stricter cholesterol guidelines broaden indications for the 'statin' drugs.
Capriotti T
Medsurg Nurs; 2003 Feb; 12(1):51-7. PubMed ID: 12619600
[No Abstract] [Full Text] [Related]
20. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Gotto AM; Farmer JA
Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
